- Home
- MTN vs LEGN Comparison
MTN vs LEGN Comparison
Compare MTN & LEGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MTN
- LEGN
- Stock Information
- Founded
- MTN 1997
- LEGN 2014
- Country
- MTN United States
- LEGN United States
- Employees
- MTN N/A
- LEGN N/A
- Industry
- MTN Services-Misc. Amusement & Recreation
- LEGN Biotechnology: Pharmaceutical Preparations
- Sector
- MTN Consumer Discretionary
- LEGN Health Care
- Exchange
- MTN Nasdaq
- LEGN Nasdaq
- Market Cap
- MTN 5.8B
- LEGN 5.4B
- IPO Year
- MTN 1997
- LEGN 2020
- Fundamental
- Price
- MTN $164.24
- LEGN $39.34
- Analyst Decision
- MTN Hold
- LEGN Strong Buy
- Analyst Count
- MTN 10
- LEGN 12
- Target Price
- MTN $186.50
- LEGN $73.91
- AVG Volume (30 Days)
- MTN 754.0K
- LEGN 1.5M
- Earning Date
- MTN 06-05-2025
- LEGN 08-08-2025
- Dividend Yield
- MTN 5.38%
- LEGN N/A
- EPS Growth
- MTN 6.60
- LEGN N/A
- EPS
- MTN 7.74
- LEGN N/A
- Revenue
- MTN $2,958,444,000.00
- LEGN $728,303,000.00
- Revenue This Year
- MTN $3.77
- LEGN $65.49
- Revenue Next Year
- MTN $3.71
- LEGN $53.76
- P/E Ratio
- MTN $21.31
- LEGN N/A
- Revenue Growth
- MTN 2.38
- LEGN 112.46
- 52 Week Low
- MTN $129.85
- LEGN $27.34
- 52 Week High
- MTN $199.45
- LEGN $60.87
- Technical
- Relative Strength Index (RSI)
- MTN 58.47
- LEGN 66.83
- Support Level
- MTN $161.52
- LEGN $38.86
- Resistance Level
- MTN $172.00
- LEGN $39.88
- Average True Range (ATR)
- MTN 3.96
- LEGN 1.41
- MACD
- MTN 0.40
- LEGN 0.34
- Stochastic Oscillator
- MTN 59.54
- LEGN 90.21
About MTN Vail Resorts Inc.
Vail Resorts Inc Bhd is a resorts and casinos company that operates mountain resorts and ski areas. The company has three business segments that include Mountain, Lodging, and Real Estate. The Mountain segment operates numerous ski resort properties that offer a variety of winter and summer activities, such as skiing, snowboarding, snowshoeing, hiking, and mountain biking. The Lodging segment owns and operates hotels and condominiums. The Real Estate segment owns, develops, and leases real estate, typically near its other properties. The company generates the vast majority of its revenue within the United States.
About LEGN Legend Biotech Corporation
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.